Published: Guidance, quality standards and advice

Showing 1 to 10 of 20

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)	TA703	26 May 2021	26 May 2021
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma	TA649	23 September 2020	23 September 2020
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab	TA629	13 May 2020	13 May 2020
Lenalidomide with rituximab for previously treated follicular lymphoma	TA627	7 April 2020	7 April 2020
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)	TA608	30 October 2019	30 October 2019
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia	TA561	27 February 2019	27 February 2019
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)	TA437	22 March 2017	22 March 2017
Skin involvement in systemic sclerosis: rituximab	ES7	7 March 2017	7 March 2017
Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab	ES1	4 November 2016	4 November 2016
Autoimmune haemolytic anaemia: rituximab	ESUOM39	10 February 2015	10 February 2015